陕西盘龙药业集团股份有限公司 第五届董事会第三次会议决议公告

Group 1 - The company held its fifth board meeting on December 26, 2025, with all nine directors present, including one attending via telecommunication [2][3] - The board approved several resolutions, including the completion of fundraising projects and the permanent allocation of surplus funds to working capital, with unanimous support [3][4] - A short-term loan application of 50 million yuan from China Agricultural Bank was also approved, with two related directors abstaining from the vote [4][5] Group 2 - The board approved the adjustment of directors and senior management, which will require shareholder approval [7][8] - A proposal to convene the first extraordinary general meeting of shareholders in 2026 was also passed unanimously [10] - The meeting is scheduled for January 16, 2026, with provisions for both on-site and online voting [11][12]